Italia markets closed

Dow Jones
39.856,52
+49,75(+0,12%)
Nasdaq
16.817,56
+22,69(+0,14%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0858
-0,0004(-0,03%)
Bitcoin EUR
63.932,03
-366,14(-0,57%)
CMC Crypto 200
1.503,64
+15,10(+1,01%)

NVCR Dec 2025 12.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,0000

0,0000

(0,00%)

In data: 12:18PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in